Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director | September 11, 2026 | September 14, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | May 14, 2026 | May 18, 2026 |
| REVA Medical, Inc.RVA.AX · Entity 11998 | Director · Chief Executive Officer | June 29, 2018 | July 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date September 11, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,546 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Sale · Disposed 5,313 · Balance 34,546 F1: This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Fulgent Genetics, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,099 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 11,117 · Balance 28,099 F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
REVA Medical, Inc.
Report date June 29, 2018 · Filed July 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 245,924.2 |
Reported balance
After 2018-06-29 transaction · row 1
1 source rowRow 1 · 2018-06-29 · Purchase · Acquired 9,815.7 · Balance 245,924.2 F1: Represents the purchase of 98,157 of the Issuer's CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange. F2: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the purchase of 98,157 of the Issuer's CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange.
F2: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 14, 2026 21:44 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 5,313 | $54.22 | $288,070.86 |
DisclosureSEC source: 0001653877-26-000006 · wk-form4_1789422288.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,546 F1 · price: This transaction was executed in multiple trades at prices ranging from $54.09 to $54.38 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 18, 2026 Filed May 20, 2026 13:25 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001653877-26-000004 · wk-form4_1779283525.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,859 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 11,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001653877-26-000001 · ownership.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,099 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 13:12 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 2,452 | $36.82 | $90,282.64 |
DisclosureSEC source: 0001653877-25-000004 · wk-form4_1754658730.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,715 F1 · price: This transaction was executed in multiple trades at prices ranging from $36.75 to $36.84 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:41 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000058 · wk-form4_1747860092.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,167 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 8,982 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074601 · ownership.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,982 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 15, 2025, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 5,481 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0000950170-24-062570 · ownership.xml · derivative · entry 2 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,481 Underlying: Common Stock · 5,481 shares Expires 2034-05-15 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 16, 2024, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062570 · ownership.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 16, 2024, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| May 13, 2024 Filed May 14, 2024 21:05 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000081 · wk-form4_1715720715.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,766 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:11 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000057 · wk-form4_1685131876.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,978 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:55 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 6,759 | $0.00 Strike: $35.58 | $0.00 |
DisclosureSEC source: 0001209191-23-031496 · doc4.xml · derivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,759 Underlying: Common Stock · 6,759 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 18, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:39 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001209191-23-000986 · doc4.xml · derivative · entry 2 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after January 3, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:39 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000986 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after January 3, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 13:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000075 · wf-form4_165365661622442.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,792 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 3,156 | $74.73 | $235,847.88 |
DisclosureSEC source: 0001209191-21-056653 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,194 F1 · price: This transaction was executed in multiple trades at prices ranging from $73.17 to $75.37 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:05 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,208 | $71.95 | $302,765.60 |
DisclosureSEC source: 0001209191-21-036518 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,350 F1 · price: This transaction was executed in multiple trades at prices ranging from $71.81 to $72.07 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:43 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035348 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,558 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| April 30, 2021 Filed Oct 29, 2021 20:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | PurchaseCommon Stock | 34 | $76.68 | $2,607.12 |
DisclosureSEC source: 0001209191-21-062074 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,228 Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:12 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 6,313 | $41.83 | $264,072.79 |
DisclosureSEC source: 0001209191-20-050690 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,809 F1 · price: This transaction was executed in multiple trades at prices ranging from $41.61 to $42.26 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2020 Filed May 22, 2020 12:21 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-031556 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,122 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 11:28 UTC | AtriCure, Inc. ATRC · Entity 2704 | PurchaseCommon Stock | 500 | $24.86 | $12,430.00 |
DisclosureSEC source: 0001209191-19-049552 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,670 F1 · price: This transaction was executed in multiple trades at prices ranging from $24.82 to $24.87 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2019 Filed May 24, 2019 12:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 4,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032570 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,170 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 19:40 UTC | REVA Medical, Inc. RVA.AX · Entity 11998 | PurchaseCommon Stock | 9,815.7 | $1.53 | $15,018.02 |
DisclosureSEC source: 0001209191-18-040511 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,924.2 F1 · shares: Represents the purchase of 98,157 of the Issuer's CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange. F2 · price: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 20:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034682 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,962 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:34 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032989 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,690 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:00 UTC | REVA Medical, Inc. RVA.AX · Entity 11998 | GrantEmployee Stock Option (right to buy) · Derivative | 226,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-18-031614 · doc4.xml · derivative · entry 2 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2028-05-16 F2 · derivative.exercise_date: The option vests and becomes exercisable as follows: 25% of the shares vest on May 16, 2019 with the remaining shares vesting at the rate of 2.0833% per month thereafter until fully vested. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:00 UTC | REVA Medical, Inc. RVA.AX · Entity 11998 | GrantCommon Stock (RSUs) | 114,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-031614 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,108.5 F1 · shares: The restricted stock units (RSUs) convert into shares of Common Stock on a one-for-one basis. The RSUs vest in three (3) equal annual installments beginning on May 16, 2019. Read SEC document |
| March 01, 2018 Filed Mar 1, 2018 21:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | PurchaseCommon Stock | 1,000 | $17.43 | $17,430.00 |
DisclosureSEC source: 0001209191-18-014940 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,469 Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:25 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | PurchaseCommon Stock | 386.5 | $6.37 | $2,461.23 |
DisclosureSEC source: 0001209191-17-050830 · doc4.xml · nonDerivative · entry 2 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,108.5 F3 · shares: Represents the purchase of 3,865 of the Issuer's CHESS Depository Interests (CDIs) trading on the Australian Securities Exchange. F2 · price: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. Read SEC document |
| August 23, 2017 Filed Aug 30, 2017 20:25 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | PurchaseCommon Stock | 407.7 | $6.37 | $2,597.46 |
DisclosureSEC source: 0001209191-17-050830 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,722 F1 · shares: Represents the purchase of 4,077 of the Issuer's CHESS Depository Interests (CDIs) trading on the Australian Securities Exchange. F2 · price: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 18:25 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | PurchaseCommon Stock | 402.4 | $5.86 | $2,359.67 |
DisclosureSEC source: 0001209191-17-049754 · doc4.xml · nonDerivative · entry 2 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,314.3 F3 · shares: Represents the purchase of 4,024 of the Issuer's Chess Depository Interests (CDIs) trading on the Australian Securities Exchange. F2 · price: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 18:25 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | PurchaseCommon Stock | 303.4 | $5.57 | $1,689.94 |
DisclosureSEC source: 0001209191-17-049754 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,911.9 F1 · shares: Represents the purchase of 3,034 of the Issuer's Chess Depository Interests (CDIs) trading on the Australian Securities Exchange. F2 · price: The purchase was executed in the form of CDIs, trading on the Australian Securities Exchange, and as such the purchase price has been converted to a USD equivalent, adjusting for the conversion ratio of 1 share of common stock per 10 CDIs, and the exchange rate on the date of the transaction. Read SEC document |
| May 19, 2017 Filed May 22, 2017 20:16 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantStock Option (right to buy) · Derivative | 58,500 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001209191-17-034532 · doc4.xml · derivative · entry 2 GROVES REGINA E · CIK 0001653877 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 58,500 shares Expires 2027-05-19 F2 · derivative.exercise_date: 25% of the shares vest on May 19, 2018, with the remaining shares vesting at 2.08333% per month thereafter until fully vested. Read SEC document |
| May 19, 2017 Filed May 22, 2017 20:16 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantCommon Stock | 29,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034532 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,608.5 F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. These restricted stock units shall vest annually on the anniversary date of the grant (May 19), with the first vesting occurring on May 19, 2018, at the rate of 33.3% annually, until fully vested. Read SEC document |
| March 21, 2017 Filed Mar 23, 2017 20:10 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 9,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022558 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,469 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 33% annually over three years from date of grant. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 17:49 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantStock Option (right to buy) · Derivative | 175,500 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001209191-17-022397 · doc4.xml · derivative · entry 2 GROVES REGINA E · CIK 0001653877 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,500 Underlying: Common Stock · 175,500 shares Expires 2027-03-20 F2 · derivative.exercise_date: 25% of the shares vest on March 20, 2018, with the remaining shares vesting at 2.08333% per month thereafter until fully vested. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 17:49 UTC | REVA Medical, Inc. RVA:AX · Entity 11998 | GrantCommon Stock | 87,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022397 · doc4.xml · nonDerivative · entry 1 GROVES REGINA E · CIK 0001653877 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,358.5 F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. These restricted stock units shall vest annually on the anniversary date of the grant (March 20), with the first vesting occurring on March 20, 2018, at the rate of 33.3% annually, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.